EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Efficacy of Dravet Syndrome Treatments in a Subset of Individuals with 2q24.3 Deletion: A-5 Patient Case Series

Daniel T Kashima iD, Esther Yoon iD, Gemma L Carvill iD, Linda C Laux

Journal of Child Neurology · 2026

DOI: 10.1177/08830738251409585 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Child Neurology, 2026. Verfasst von Daniel T Kashima und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsies, Myoclonic, Chromosomes, Human, Pair 2, Chromosome Deletion. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dravet syndrome (DS) is a developmental and epileptic encephalopathy often resulting from haploinsufficiency of the voltage-gated sodium channel (VGSC) gene SCN1A located on chromosome 2q24.3. Although single-nucleotide changes account for the majority of cases, rare cases are due to 2q24.3 microdeletions involving SCN1A . The 2q24.3 region surrounding SCN1A contains a cluster of VGSC genes including SCN2A , SCN3A , SCN7A , and SCN9A . Prior publications reported larger 2q24.3 deletions affecting multiple VGSC genes being associated with a more severe phenotype. Consensus recommendations for epilepsy therapies do not exist for DS patients with 2q24.3 deletion involving other VGSC genes. To address this gap, we qualitatively assessed the therapy response in 5 patients with 2q24.3 microdeletions. We found evidence of efficacy for valproic acid, clobazam, and cannabidiol whereas levetiracetam and phenobarbital were not beneficial. Additional studies are necessary to examine the efficacy of fenfluramine and the ketogenic diet.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsies, MyoclonicChromosomes, Human, Pair 2Chromosome DeletionHumansFemaleMaleNAV1.1 Voltage-Gated Sodium ChannelChild, PreschoolTreatment OutcomeChildInfant

Stichwörter der Autor:innen

2q243 deletionDravet syndromeantiseizure medicationepilepsysodium channel

Substanzen

AnticonvulsantsNAV1.1 Voltage-Gated Sodium ChannelSCN1A protein, human

Autor:innen und Institutionen

  • Division of Neurology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
  • Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Medical Scientist Training Program, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

ORCID-Profile: Daniel T Kashima, Esther Yoon, Gemma L Carvill

Förderung

  • NICHD NIH HHS

Zitieren

APA

Kashima, D. T., Yoon, E., Carvill, G. L., & Laux, L. C. (2026). Efficacy of Dravet Syndrome Treatments in a Subset of Individuals with 2q24.3 Deletion: A-5 Patient Case Series. Journal of Child Neurology. https://doi.org/10.1177/08830738251409585

Vancouver

Kashima DT, Yoon E, Carvill GL, Laux LC. Efficacy of Dravet Syndrome Treatments in a Subset of Individuals with 2q24.3 Deletion: A-5 Patient Case Series. Journal of Child Neurology. 2026. doi:10.1177/08830738251409585

BibTeX
@article{Kashima2026,
  author = {Kashima, Daniel T and Yoon, Esther and Carvill, Gemma L and Laux, Linda C},
  title = {Efficacy of Dravet Syndrome Treatments in a Subset of Individuals with 2q24.3 Deletion: A-5 Patient Case Series},
  journal = {Journal of Child Neurology},
  year = {2026},
  doi = {10.1177/08830738251409585}
}
Kostenlos starten →